Influence of ADAM10 Polymorphisms on Plasma Level of Soluble Receptor for Advanced Glycation End Products and The Association With Alzheimer’s Disease Risk

• Published in: Frontiers in genetics Vol. 9; p. 540
• Main Authors: Huang, Wen-Hui, Chen, Wei, Jiang, Lian-ying, Yang, Yi-Xia, Yao, Li-Fen, Li, Ke-Shen
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 13.11.2018
• Subjects: ADAM10; Alzheimer’s disease; Genetics; RAGE; single nucleotide polymorphism (SNP); soluble receptor for advanced glycation end products; ADAM10; RAGE; Alzheimer’s disease; soluble receptor for advanced glycation end products; single nucleotide polymorphism (SNP)
• DOI: 10.3389/fgene.2018.00540
• ISSN: 1664-8021

To determine the role of A disintegrin and metalloproteinase 10 (ADAM10) in genetic susceptibility to Alzheimer's disease (AD) in a representative Chinese sample, we genotyped 362 AD patients and 370 healthy controls for the rs514049A/C and rs653765C/T polymorphisms in the ADAM10 promoter using the SNaPshot technique. We also examined the potential impact of these polymorphisms on the plasma level of soluble receptor for advanced glycation end products (sRAGE), a decoy receptor whose reduction has been associated with a higher risk of AD. Additionally, a meta-analysis was performed using the present study and the largest GWAS from the International Genomics of Alzheimer's Project (IGAP). No significant differences were found in the distributions of genotypes or alleles between AD patients and control subjects. However, age-at-onset stratification analysis revealed that there were significant differences in the genotypes ( = 0.015) and alleles ( = 0.006) of the rs653765 SNP. Furthermore, patients with the rs653765 CC genotype showed a lower ADAM10 level and a faster cognitive deterioration than those in patients with the CT/TT genotype in late-onset AD (LOAD), and the rs653765 CC polymorphism was able to regulate the production of the ADAM10 substrate sRAGE. In contrast, the rs514049 polymorphism was not statistically associated with AD. In the meta-analysis, we observed that both rs514049 (A allele vs. C allele, = 0.002) and rs653765 (C allele vs. T allele, = 0.004) were associated with AD risk. The present study indicated that the rs653765 polymorphism might be associated with the risk and development of LOAD; in particular, the risk genotype, CC, may decrease the expression of ADAM10, influencing the plasma levels of sRAGE, and thus may be correlated with the clinical progression of AD.